---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-021087"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T11:23:50.184902+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q4 net loss $42.8M; ziftomenib KOMET-001 enrollment on track for mid-2024

## Summary
- Net loss for Q4 2023 was $42.8M vs $33.1M in Q4 2022; full year loss $152.6M vs $135.8M.
- Cash and investments $424M at Dec 31, 2023; pro forma $570M after Jan 2024 private placement, runway into 2027.
- Enrollment of 85 patients in registration-directed KOMET-001 trial of ziftomenib for NPM1-m AML expected by mid-2024.
- Preliminary KOMET-007 data: 100% CR in frontline NPM1-m/KMT2A-r AML with 7+3; 53% ORR in R/R with ven/aza; no differentiation syndrome.
- First patient dosed in KOMET-008 (ziftomenib + gilteritinib, FLAG-IDA or LDAC); collaboration with Mirati for KO-2806 + adagrasib.

## SEC filing metadata
- accession: 0000950170-24-021087
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017024021087/0000950170-24-021087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017024021087/kura-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-021087
- JSON: https://secwatch.observer/filing/0000950170-24-021087.json
- Plain text: https://secwatch.observer/filing/0000950170-24-021087.txt

## Key facts
- Earnings Releases
  Kura Oncology, Inc. reported financial results for fourth quarter and year ended December 31, 2023.
  - Period: fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On February 27, 2024, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2023 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000095017024021087/0000950170-24-021087-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.